| Bioactivity | PK14105 is a biological evaluation as a potential radioligand for PET studies of PBBS receptors.in vivo binding experiments, in which PK 14105 was injected into rats with unilaterally lesioned striata, demonstrate that PK 14105 rapidly crosses the blood-brain-barrier and that there is a marked retention of radioactivity in the lesioned striatum not seen in the unlesioned striatum or cerebellar vermis[1]. It can also inhibit receptor ligands, calcium channel ligands and co-transporter in all salivary glands[2]. | ||||||||||||
| Name | PK14105 | ||||||||||||
| CAS | 107257-28-3 | ||||||||||||
| Formula | C21H20FN3O3 | ||||||||||||
| Molar Mass | 381.40 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Pascali C et al. The radiosynthesis of [18F]PK 14105 as an alternative radioligand for peripheral type benzodiazepine binding sites. Int J Rad Appl Instrum A. 1990;41(5):477-82. [2]. Franklin C. Wong et al. Affinity Labeling of Membrane Receptors Using Tissue-Penetrating Radiations. Biomed Res Int. 2013, 503095. |